GFAP

There are 670 papers on GFAP in aging research: 31 trials and 420 observational studies in people, 176 in animals, 7 in cells, 30 reviews. The newest story, Nov 7, 2026: “Some blood amino acids linked to lower Parkinson’s risk”.

Biomarker

670 papers study it343 findings

29 new papers in 30 daysSee all 670 papers on GFAP

At a glance

Higher plasma GFAP is associated with lower odds of reaching 90 without cognitive impairment in a preprint cohort of initially cognitively unimpaired women. Human cohorts also link GFAP with dementia risk, cognitive decline, and brain amyloid. A hearing-aid trial reports lower GFAP, while a dasatinib-plus-quercetin trial reports higher cerebrospinal fluid GFAP.

343 findings in 257 papers from 1995 to 2026, 66 of them since April 2026

“Higher plasma GFAP levels at baseline and 6 months were independently and significantly associated with smaller percentage improvements in RBANS scores over 6 months.”
Plasma GFAP and Amyloid Pathology Predict Cognitive Response to Multidomain Interventions in MCIAging and disease2025doi:10.14336/ad.2025.0646
  • Human trial31
  • Humans420
  • Animals176
  • Cells7

Interventions

32

Dasatinib + quercetin

upin humans2

2 studies
  1. Dasatinib + quercetin increases GFAP in humans.

    “Data revealed a statistically significant increase in CSF GFAP levels post-treatment versus baseline (p = 0.0285, ).”

    Human trialcerebrospinal fluid12 weeksn = 5

    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

    Nature medicine

  2. Dasatinib + quercetin increases GFAP in humans (open-label 12-week pilot in early-stage Alzheimer's disease) (t(4)=3.354, p=0.028).

    “CNS levels of IL-6 and GFAP increased from baseline to post-treatment (t(4)=3.913, p=008 and t(4)=3.354, p=0.028, respectively)”

    Human trialopen-label 12-week pilot in early-stage Alzheimer's diseasecentral nervous system12 weeksn = 5

    Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

    Research squarePreprint

  3. Dasatinib + quercetin increases GFAP in humans.

    “Using the SIMOA assays, there were no pre- to post-treatment changes in plasma or CSF protein levels with the exception of a significant increase of GFAP levels in CSF.”

    Human trialcerebrospinal fluid12-weekn = 5

    Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

    Research squarePreprint

More on Dasatinib + quercetin

Physical activity

downin humans2

2 studies
  1. Physical activity is linked with lower GFAP in humans (B = -0.08, 95% CI: -0.15 to -0.01).

    “GFAP: B = -0.08, 95% CI: -0.15 to -0.01)”

    Humansmales

    Midlife activity linked to lower brain-related markers in men

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. Physical activity is linked with lower GFAP in humans (only in Val/Val male participants).

    “higher PA was associated with lower plasma GFAP only in Val/Val male participants”

    Humansonly in Val/Val male participantsplasmamalesn = 180

    BDNF Val66Met polymorphism moderates associations between physical activity and neurocognitive outcomes in older adults

    Alzheimer's & dementia (New York, N. Y.)

More on Physical activity

Neflamapimod

downin humans1

1 study
  1. Neflamapimod decreases GFAP (−17.4 pg/mL).

    “during the 32-week extension period, there was a significant reduction in this protein biomarker while receiving neflamapimod (−17.4 pg/mL) compared with both the start of the extension or the change while on placebo (+6.7 pg/mL”

    Human trialplasma6 weeks

    Targeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies

    Cells

  2. Neflamapimod decreases GFAP in humans (dementia with Lewy bodies).

    “In DLB, neflamapimod 40 mg TID increased the plasma Aβ42/40 ratio and reduced plasma GFAP levels”

    Human trialdementia with Lewy bodiesplasma40 mg three times daily

    Targeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies

    Cells

More on Neflamapimod

Hearing aids

downin humans1

1 study
  1. Hearing aids decrease GFAP in humans (difference: −0.175; 95% CI: −0.322, −0.028).

    “Covariate-adjusted intention-to-treat analyses of three-year change in the primary analytic sample revealed that the hearing intervention was associated with a slower rise in GFAP”

    Human trial3 yearsn = 164

    Effects of hearing intervention on blood-based biomarkers of neuroinflammation and neurodegeneration: a secondary analysis of the ACHIEVE randomised controlled trial

    EClinicalMedicine

  2. Hearing aids decrease GFAP in humans (untreated hearing loss without substantial cognitive impairment) (difference: -0.175; 95% CI: -0.322, -0.028).

    “hearing intervention was associated with a slower rise in GFAP (intervention: -0.026; 95% CI: -0.144, 0.093, control: 0.149; 95% CI: 0.039, 0.260; difference: -0.175; 95% CI: -0.322, -0.028; p-difference: 0.019)”

    Human trialuntreated hearing loss without substantial cognitive impairmentplasma3 yearsn = 164

    Effects of hearing intervention on blood-based biomarkers of neuroinflammation and neurodegeneration: a secondary analysis of the ACHIEVE randomised controlled trial

    EClinicalMedicine

More on Hearing aids

Progesterone

downin mice1

1 study
  1. Progesterone prevents GFAP in MPTP-lesioned OVX mice.

    “Striatal glial fibrillary acidic protein (GFAP), an astrogliosis marker, levels were elevated in MPTP-lesioned mice and this was similarly prevented with the hormonal treatment alone or in combination.”

    Animalsin MPTP-lesioned OVX micestriatum10 daysfemales

    Raloxifene and progesterone neuroprotection in a female mouse model of Parkinson's disease

    Frontiers in neuroscience

More on Progesterone

Raloxifene

downin mice1

1 study
  1. Raloxifene prevents GFAP in MPTP-lesioned OVX mice.

    “Striatal glial fibrillary acidic protein (GFAP), an astrogliosis marker, levels were elevated in MPTP-lesioned mice and this was similarly prevented with the hormonal treatment alone or in combination.”

    Animalsin MPTP-lesioned OVX micestriatum10 daysfemales

    Raloxifene and progesterone neuroprotection in a female mouse model of Parkinson's disease

    Frontiers in neuroscience

More on Raloxifene

Resistance training

downin humans1

1 study
  1. Resistance training decreases GFAP in humans.

    “notably, resistance-based programs also induced additional reductions in GFAP and tau protein.”

    Review

    Effects of physical exercise on neurofilament light chain in multiple sclerosis and other neurological disorders: A systematic review

    Multiple sclerosis and related disorders

More on Resistance training

Computerized cognitive remediation therapy

downin humans1

1 study
  1. Computerized cognitive remediation therapy decreases GFAP in humans (P < 0.001).

    “Plasma GFAP levels significantly decreased in the intervention group compared to the control group (P < 0.001)”

    Human trial12 weeks

    A study on the effects of CCRT on cognitive function and blood biomarkers in community-dwelling older adults with MCI

    BMC geriatrics

More on Computerized cognitive remediation therapy

Rapamycin

upin mice1

1 study
  1. Rapamycin increases GFAP in mice.

    “rapamycin treatment further increased GFAP levels in the striatum of both sexes”

    Animalsstriatum14 ppmchronic

    Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Rapamycin

Nicotinamide riboside

downin mice1

1 study
  1. Nicotinamide riboside decreases GFAP in 5xFAD mice, following NR treatment.

    “GFAP staining mirrored this trend, implicating reactive astrogliosis as a mechanism for elevated glutamate.”

    Animalsin 5xFAD mice, following NR treatmenthippocampal dentate gyrus

    In vivo imaging of glutamate uncovers the neuroprotective effects of nicotinamide riboside on excitotoxicity in an Alzheimer's mouse model

    Alzheimer's research & therapy

More on Nicotinamide riboside

Sodium lactate

downin humans1

1 study
  1. Sodium lactate decreases GFAP in humans (p < 0.001).

    “reductions in plasma BD‐tau ( p <0.001), pTau217 ( p <0.001), pTau181 ( p <0.001), GFAP ( p <0.001), and NfL ( p <0.001) in both AD and CH groups after lactate infusion”

    Human trialplasma120 minutes

    Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition; the LEAN study

    AAIC 2025 abstract

More on Sodium lactate

Biperiden

no changein humans1

1 study
  1. Biperiden showed no clear effect on GFAP in humans (acute phase post-TBI).

    “While biperiden treatment did not significantly alter biomarker levels across the overall cohort”

    Human trialacute phase post-TBIserum

    Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden

    AAIC 2025 abstract

More on Biperiden

Hearing intervention

downin humans1

1 study
  1. Hearing intervention decreases GFAP in humans (ARIC participants with untreated hearing loss) (mean: -0.415; 95% CI: -0.712, -0.118).

    “Among ARIC participants, intervention resulted in lower 3‐year GFAP (mean:‐0.415;95%CI:‐0.712,‐0.118)”

    Human trialARIC participants with untreated hearing loss3 years

    Effects on blood neurodegeneration biomarkers of a randomized hearing rehabilitation intervention: ACHIEVE Clinical Trial update

    AAIC 2025 abstract

More on Hearing intervention

Meal

downin humans1

1 study
  1. Meal decreases GFAP in humans (post-prandial).

    “there was very strong evidence that eating decreased GFAP levels”

    Human trialpost-prandialplasman = 30

    EFFECTS OF FASTING STATUS ON BLOOD-BASED NEURODEGENERATIVE BIOMARKERS IN OLDER ADULTS

    GSA 2024 abstract

More on Meal

Nutritional blend

no changein humans1

1 study
  1. Nutritional blend showed no clear effect on GFAP in humans (community-dwelling) (-3.28 pg/mL, 95% CI: -17.25, 10.69).

    “GFAP between-group difference: -3.28 pg/mL, 95%CI: -17.25, 10.69; p=0.644”

    Human trialcommunity-dwellingplasma1 yearn = 289

    Effect of a 1-Year Nutritional Blend Supplementation on Plasma p-tau181 and GFAP Levels among Community-Dwelling Older Adults: A Secondary Analysis of the Nolan Trial

    JAR life

More on Nutritional blend

All 32

Effects

21

Cognitive function

downin humans5no changein humans1

5 studies
  1. GFAP was not clearly linked with cognitive function in humans (interaction of baseline levels of GFAP and p-tau217) (β = -0.076, p = 0.094).

    “However, baseline levels of GFAP and p ‐tau217 did not show a significant interaction (βTime*pTau217*GFAP baseline = ‐0.076; p = 0.094)”

    Humansinteraction of baseline levels of GFAP and p-tau217plasma10 yearsn = 354

    Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults

    AAIC 2025 abstract

  2. GFAP is linked with worse cognitive function in humans (cognitively unimpaired individuals with p-tau217+ and higher annual GFAP fast.rate) (β = -0.158, p < 0.001).

    “Participants with p ‐tau217+ and higher annual GFAPfast.rate showed a significantly faster cognitive decline (βTime*pTau217*GFAP fast.rate = ‐0.158; p <0.001) than those with non‐GFAP fast.rate”

    Humanscognitively unimpaired individuals with p-tau217+ and higher annual GFAP fast.rateplasma10 yearsn = 354

    Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults

    AAIC 2025 abstract

  3. GFAP is linked with worse cognitive function in amyloid-negative individuals with high white matter hyperintensities (Fazekas 2-3) (β: -0.194, p = 0.0390).

    “In the Fz2‐3 group, hippocampal atrophy (Table 1; β: ‐0.179, p = 0.0440) and cognitive decline (Table 1; β: ‐0.194, p = 0.0390) was associated with plasma GFAP.”

    Humansin amyloid-negative individuals with high white matter hyperintensities (Fazekas 2-3)

    Vascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid‐negative individuals

    AAIC 2025 abstract

  4. GFAP is linked with worse cognitive function in humans (linear β coefficients: -0.022 to -0.300).

    “Higher plasma levels of p ‐tau181, GFAP and NfL were associated with a greater decline in global cognitive function, verbal fluency, episodic memory and psychomotor speed (linear β coefficients: ‐0.022 to ‐0.300).”

    Humansplasmaup to 11 years

    Plasma biomarkers of Alzheimer's disease and related dementias and changes in cognitive function in US and Australian older individuals

    AAIC 2025 abstract

  5. GFAP is linked with worse cognitive function in humans (dementia-free older adults) (β -1.48, 95% C.I. -2.44, -0.52, P = 0.003).

    “GFAP associated with global cognition (β -1.48, 95% C.I. -2.44, -0.52, P = 0.003)”

    Humansdementia-free older adultsn = 147

    Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort

    Brain communications

  6. GFAP is linked with worse cognitive function in humans.

    “Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations.”

    Humans

    Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)

    American journal of epidemiology

Dementia

mediatesin humans2

2 studies
  1. GFAP is linked with dementia in humans (APOE4-associated risk).

    “circulating GFAP served as a shared protein mediator for ACD, AD and VaD”

    HumansAPOE4-associated riskn = 51,623

    Brain and blood markers link APOE4 to dementia risk

    Research SquarePreprint

  2. GFAP is linked with dementia in humans (edentulism association) (12.0%).

    “GFAP mediated 9.8% and 12.0% of the cognitive impairment and dementia associations”

    Humansedentulism association10-yearn = 4,238

    Blood markers account for a small part of tooth loss–dementia link

    Alzheimer's & dementia : the journal of the Alzheimer's Association

More on Dementia

Cognitive impairment

mediatesin humans2OR 1.114

2 studies
  1. GFAP is linked with cognitive impairment in humans (association between comorbid insomnia and anxiety and cognitive outcomes).

    “GFAP showing a modest but significant independent contribution”

    Humansassociation between comorbid insomnia and anxiety and cognitive outcomes

    Synergistic association of insomnia and anxiety with cognitive impairment and dementia in older adults

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. GFAP is linked with cognitive impairment in humans (age-related risk; independent validation cohorts) (Duke CSF OR 1.114, 95% CI 1.069–1.206; ADNI OR 1.004, 95% CI 1.000–1.009; UK Biobank OR 1.030, 95% CI 1.026–1.034).

    “Across validation cohorts, GFAP consistently showed significant mediation effects”

    Humansage-related risk; independent validation cohortsCSF and plasma

    Identifying a proteomics signature of cognitive impairment and dementia in blood and cerebrospinal fluid through a mediation analysis framework

    Neurobiology of aging

More on Cognitive impairment

Executive and attentional performance

mediatesin humans1

1 study
  1. GFAP is linked with executive and attentional performance in humans.

    “GFAP partially mediated associations between air pollution exposure and worsening executive and attentional performance.”

    HumansPartial mediation of associations with air pollution exposure in cognitively unimpaired individuals at increased risk of Alzheimer's diseasen = 226

    Air pollution linked to inflammation markers, mainly in women

    Alzheimer's & dementia : the journal of the Alzheimer's Association

Global cognition

downin humans1

1 study
  1. GFAP is linked with worse global cognition in humans (simultaneous models of baseline-adjusted follow-up cognition) (β = -0.066, q = 0.002).

    “GFAP was associated with lower executive function (β = -0.047, q = 0.007), memory (β = -0.047, q = 0.032), and global cognition (β = -0.066, q = 0.002)”

    Humanssimultaneous models of baseline-adjusted follow-up cognition6 yearsn = 1,170

    Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains

    Alzheimer's & dementia (Amsterdam, Netherlands)

Memory

downin humans1

1 study
  1. GFAP is linked with worse memory in humans (simultaneous models of baseline-adjusted follow-up cognition) (β = -0.047, q = 0.032).

    “GFAP was associated with lower executive function (β = -0.047, q = 0.007), memory (β = -0.047, q = 0.032)”

    Humanssimultaneous models of baseline-adjusted follow-up cognition6 yearsn = 1,170

    Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains

    Alzheimer's & dementia (Amsterdam, Netherlands)

Executive function

downin humans1

1 study
  1. GFAP is linked with worse executive function in humans (simultaneous models of baseline-adjusted follow-up cognition) (β = -0.047, q = 0.007).

    “GFAP was associated with lower executive function (β = -0.047, q = 0.007)”

    Humanssimultaneous models of baseline-adjusted follow-up cognition6 yearsn = 1,170

    Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains

    Alzheimer's & dementia (Amsterdam, Netherlands)

Amyloid beta burden

no changein humans1

1 study
  1. GFAP was not clearly linked with amyloid beta burden in humans.

    “Higher plasma GFAP was associated with increased posterior cerebral artery (PCA)-defined WMH volume, but not with global amyloid or episodic memory.”

    Humansplasman = 439

    Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest-old, the LifeAfter90 Study

    Alzheimer's & dementia : the journal of the Alzheimer's Association

More on Amyloid beta burden

Episodic memory

downin humans1

1 study
  1. GFAP is linked with worse episodic memory in humans (longitudinal).

    “Higher baseline GFAP was associated with worse longitudinal episodic memory, exclusively in women.”

    Humanslongitudinalfemales

    Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly

    bioRxiv : the preprint server for biologyPreprint

Hippocampal volume

downin humans1

1 study
  1. GFAP is linked with lower hippocampal volume in amyloid-negative individuals with high white matter hyperintensities (Fazekas 2-3) (β: -0.179, p = 0.0440).

    “In the Fz2‐3 group, hippocampal atrophy (Table 1; β: ‐0.179, p = 0.0440) and cognitive decline (Table 1; β: ‐0.194, p = 0.0390) was associated with plasma GFAP.”

    Humansin amyloid-negative individuals with high white matter hyperintensities (Fazekas 2-3)

    Vascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid‐negative individuals

    AAIC 2025 abstract

All 21

Upstream

31

APOE

downin humans1upin humans1

2 studies
  1. APOE is linked with lower GFAP in PSEN1 E280A carriers (f2=0.247).

    “APOE3 Ch heterozygosity was associated with significantly attenuated age-related increases in GFAP (f2=0.247)”

    Humansin PSEN1 E280A carriers

    Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers

    Research SquarePreprint

  2. APOE is linked with higher GFAP in humans (APOE ε4 carriage and slow gait in mild cognitive impairment) (F1, 312 = 7.17, p = 0.008).

    “individuals with APOE ε4 and SG had significantly higher plasma GFAP levels.”

    HumansAPOE ε4 carriage and slow gait in mild cognitive impairmentplasma

    Elevated plasma GFAP levels in MCI link APOE ε4 allele with impaired gait speed

    GeroScience

More on APOE

Alzheimer's disease

upin humans1downin mice1

2 studies
  1. Alzheimer's disease is linked with higher GFAP in Alzheimer disease.

    “p-tau181 and GFAP showed its greatest increase in Alzheimer disease.”

    Humansin Alzheimer disease

    Population-based reference equations and Z-scores for blood biomarkers of neurodegenerative diseases

    medRxivPreprint

  2. Alzheimer's disease decreases GFAP in mice (3xTg-AD mice).

    “Our results show a severe atrophy in GFAP cytoskeleton in all cognitive areas”

    Animals3xTg-AD micecognitive areasmales

    Neuroanatomical and morphometric study of S100β positive astrocytes in the entorhinal cortex during ageing in the 3xTg-Alzehimer's disease mouse model

    Neuroscience letters

More on Alzheimer's disease

APP

upin mice2

2 studies
  1. APP increases GFAP in Tg2576 mice.

    “the astrocyte marker GFAP was increased in Tg2576 compared to wild‐type mice”

    Animalsin Tg2576 micebrain

    Architectural degeneration and dysfunction of Cerebral vessels in a mouse model of Alzheimer's disease

    AAIC 2025 abstract

  2. APP increases GFAP in ob/ob mice.

    “increased levels of glial fibrillary acidic protein (GFAP), an astrocyte marker, in AppNL-F/wt knock-in; ob/ob mice”

    Animalsin ob/ob mice

    Increased levels of Aβ42 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

More on APP

Rest-activity rhythms

no changein humans1

1 study
  1. Rest-activity rhythms were not clearly linked with GFAP in humans.

    “RAR metrics were not significantly associated with GFAP, NfL, or pTau181/(Aβ42/Aβ40) in the plasma biomarker models.”

    Humans

    Stronger rest-activity rhythms link to better executive function

    Frontiers in aging neuroscience

More on Rest-activity rhythms

Homo sapiens

upin humans1

1 study
  1. Homo sapiens are linked with higher GFAP in humans (Down syndrome) (posterior distributions ≥ 99.12%).

    “Cluster of differentiation 14, CXCL17, EDA2R, GFAP, IGFBP2, NFL, SEPTIN3, and SPON1 exhibited longitudinal increase, while CBLN4 decreased (all posterior distributions ≥ 99.12%), with age.”

    HumansDown syndromeplasman = 59

    Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome

    Neurology

More on Homo sapiens

Age

upin humans1+2.2% per year

1 study
  1. Age is linked with higher GFAP in humans (+2.2% per year).

    “expected NfL and GFAP concentrations increased by an average of 2.6% and 2.2% per year, respectively.”

    Humans

    Population-based reference equations and Z-scores for blood biomarkers of neurodegenerative diseases

    medRxivPreprint

Subjective aging

no changein humans1

1 study
  1. Subjective aging was not clearly linked with GFAP in humans.

    “Subjective age and SPA were unrelated to GFAP, Aβ42/Aβ40 ratio, and p-tau181.”

    Humansn = 3,401

    Subjective aging and neurobiomarkers of brain health in the health and retirement study

    Psychiatry research

Female sex

upin humans1

1 study
  1. female sex is linked with higher GFAP in humans.

    “Unimpaired women exhibited higher plasma GFAP levels than men (N=584).”

    Humansfemalesn = 584

    Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly

    bioRxiv : the preprint server for biologyPreprint

MYO6

downin mice1

1 study
  1. MYO6 decreases GFAP in mice (lack of myosin VI).

    “and an increase of the level of GFAP, the marker of glia cells, in adult mice.”

    Animalslack of myosin VIbrain

    Lack of unconventional myosin VI is associated with brain enlargement and gliosis progressing with age

    Acta neurobiologiae experimentalis

More on MYO6

amyloid pathology

upin humans1

1 study
  1. amyloid pathology is linked with higher GFAP in subjective cognitive decline with amyloid positivity and high vascular burden (A+V+).

    “GFAP levels were highest in A+V‐ and significantly elevated in A+V+( p <0.001 and p = 0.028)”

    Humansin subjective cognitive decline with amyloid positivity and high vascular burden (A+V+)

    Deciphering the Prodrome: Synergistic Amyloid and Vascular Pathologies in Subjective Cognitive Decline – Insights from the Southeast Asian BIOCIS Study

    AAIC 2025 abstract

All 31

Associations

163

Cognitive function

downin humans17upin humans1mixedin humans1

19 studies
  1. GFAP predicts cognitive function in MCI patients (AUC = 0.805, P < 0.001).

    “reduction in GFAP levels significantly predicted cognitive improvement in MCI patients (AUC = 0.805, P < 0.001)”

    Human trialin MCI patients

    A study on the effects of CCRT on cognitive function and blood biomarkers in community-dwelling older adults with MCI

    BMC geriatrics

  2. GFAP predicts cognitive function in humans.

    “Higher plasma GFAP levels at baseline and 6 months were independently and significantly associated with smaller percentage improvements in RBANS scores over 6 months.”

    Human trialmultidomain interventions6 monthsn = 300

    Plasma GFAP and Amyloid Pathology Predict Cognitive Response to Multidomain Interventions in MCI

    Aging and disease

  3. GFAP is associated with cognitive function in humans.

    “Hippocampal GFAP was associated with increased odds of Alzheimer's dementia and faster decline in global cognition, episodic memory, semantic memory, and perceptual speed.”

    Humanshippocampus

    Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  4. GFAP is associated with cognitive function in humans (CL ≤ 10).

    “Elevated GFAP levels were correlated with reduced cortical thickness and poorer cognitive performance in the CL ≤ 10 group”

    HumansCL ≤ 10

    Associations of plasma GFAP and P-tau217 with imaging ATN markers and cognitive decline across Centiloid scales

    The Lancet regional health. Western Pacific

  5. GFAP predicts cognitive function in cognitively unimpaired individuals at-risk of Alzheimer's disease (β = -0.10, p = 0.010).

    “higher plasma GFAP being associated with mPACC decline in men only (β GFAP_men = ‐0.10, p = 0.010).”

    Humansin cognitively unimpaired individuals at-risk of Alzheimer's diseasemales

    Plasma biomarkers predict long‐term longitudinal cognitive decline in individuals at‐risk for Alzheimer's disease: differences across demographic groups

    AAIC 2025 abstract

  6. GFAP is associated with cognitive function in humans.

    “Higher midlife NfL and GFAP were associated with faster declines in global cognition and language.”

    Humans

    Change in Plasma Biomarkers of Alzheimer’s Disease From Midlife to Late-Life and Associations With Cognitive Change

    GSA 2025 abstract

  7. GFAP predicts cognitive function in humans (dementia-free participants).

    “higher GFAP was associated with worse performance on processing speed and verbal fluency”

    Humansdementia-free participantsplasman = 1,356

    Alzheimer disease blood biomarkers and cognition in midlife

    AAIC 2025 abstract

  8. GFAP is associated with cognitive function in humans.

    “GFAP levels were negatively associated with PACC in women ( n = 578, ß=‐4.58, p = .006)”

    Humansserumfemalesn = 949

    Sex and Age Differences in the Association of Serum GFAP Levels with Cognitive Decline in Cognitively Unimpaired Individuals: Results from the A4 Study

    AAIC 2025 abstract

  9. GFAP is associated with cognitive function in humans (subjective cognitive decline) (β time × biomarker slope = -0.02 to -0.04).

    “Longitudinal increases in pTau217 and GFAP were associated with cognitive decline over time in all domains”

    Humanssubjective cognitive declineplasma4.8 (2.6) yearsn = 298

    Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline

    JAMA network open

  10. GFAP is associated with cognitive function in humans (β: -0.022 to -0.300).

    “Higher levels of p-tau181 (β: -0.001 to -0.212), GFAP (β: -0.022 to -0.300) and NfL (β: -0.022 to -0.219), and lower levels of Aβ42/40 ratio (β: 0.015 to 0.126) were associated with greater cognitive decline over time.”

    Humans

    Plasma biomarkers of alzheimer's disease and related dementias are associated with cognitive change in community-dwelling older individuals in Australia and the US

    GeroScience

All 19

Alzheimer's disease

upin humans15mixedin humans1HR 1.36

16 studies
  1. Alzheimer's disease is associated with GFAP in humans (stepwise increase from cognitively unimpaired to dementia).

    “stepwise increases of p-tau217, NfL and GFAP from cognitively unimpaired to dementia (p < 0.05).”

    Humansstepwise increase from cognitively unimpaired to dementiaplasman = 967

    Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

    NPJ dementia

  2. GFAP is associated with Alzheimer's disease in humans.

    “Hippocampal GFAP was associated with increased odds of Alzheimer's dementia and faster decline in global cognition, episodic memory, semantic memory, and perceptual speed.”

    Humanshippocampus

    Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. Alzheimer's disease is associated with GFAP in humans (A+ compared with A− subjects) (64.7 vs. 47.6 pg/mL; p = 0.001).

    “Plasma GFAP concentrations were higher in A+ compared with A− subjects (64.7 vs. 47.6 pg/mL; p = 0.001)”

    HumansA+ compared with A− subjects

    Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform

    Alzheimer's research & therapy

  4. GFAP predicts Alzheimer's disease in cognitively unimpaired individuals (AUC of 0.67 (95% CI: 0.59–0.76)).

    “Plasma GFAP discriminated amyloid status (A + vs. A- individuals) with an AUC of 0.67 (95% CI: 0.59–0.76).”

    Humansin cognitively unimpaired individuals

    Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform

    Alzheimer's research & therapy

  5. Alzheimer's disease is associated with GFAP in humans across the clinical continuum.

    “We observed a progressive decline in the Aβ42/Aβ40 ratio and elevations in p-tau217 and GFAP across the clinical continuum.”

    Humansacross the clinical continuumplasman = 318

    Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort

    Alzheimer's research & therapy

  6. Alzheimer's disease is associated with GFAP in humans (Alzheimer's disease).

    “Furthermore, individuals with AD exhibited marked pineal cellular depletion compared with controls, alongside elevated GFAP expression.”

    HumansAlzheimer's diseasepineal glandn = 7

    The pineal gland in ageing and alzheimer's disease: age-related molecular changes

    Brain structure & function

  7. GFAP predicts Alzheimer's disease in humans (individuals with Down syndrome).

    “as well as pTau181 levels and GFAP levels, were predictive of percentiles indicating AD in DS.”

    Humansindividuals with Down syndromen = 157

    Linear regression prediction model for an outcome of Alzheimer's Disease in Down Syndrome including BPSD‐DSII sections and Alzheimer's Disease fluid biomarkers

    AAIC 2025 abstract

  8. Alzheimer's disease is associated with GFAP in humans (AD vs CU).

    “significant main effects between GFAP groups and age, diagnosis of AD”

    HumansAD vs CU

    The relationship between neuroinflammation and clinical features of dementia: An investigation of GFAP levels in Alzheimer's disease and related disorders

    AAIC 2025 abstract

  9. GFAP predicts Alzheimer's disease in humans (distinguishing probable AD from normal cognition) (AUC 0.869).

    “The area under the ROC curve (AUC) was 0.886 for p-tau181, 0.655 for p-tau217, and 0.869 for GFAP.”

    Humansdistinguishing probable AD from normal cognitionplasma

    The exploration of using plasma biomarkers of p-tau217 and p-tau181 for screening Alzheimer's disease in very elderly people

    Frontiers in neurology

  10. Alzheimer's disease is associated with GFAP in humans (d = 0.88, p<.001).

    “MCIAD+ had higher plasma GFAP and NfL than both MCIAD- (GFAP: p<.001, d = 0.88, NfL: p<.001, d = 0.86) and CNAD- (GFAP: p<.001, d = 0.80; NfL: p<.001, d = 0.89).”

    Humansn = 378

    Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217

    The journal of prevention of Alzheimer's disease

All 18

More on Alzheimer's disease

Dementia

upin humans7upin reviews1HR 1.762–2.65

8 studies
  1. GFAP is linked with a higher risk of dementia in humans (HR = 2.65, 95% CI: 2.17-3.25).

    “higher GFAP concentrations were specifically associated with dementia (HR = 2.65, 95% CI: 2.17-3.25)”

    Humansplasman = 19,645

    The interplay of air pollution with plasma neurodegenerative markers and metabolome for dementia, Parkinson's disease and all-cause mortality risks and transitions: The UK Biobank study

    Ecotoxicology and environmental safety

  2. GFAP is linked with a higher risk of dementia in humans.

    “Higher serum GFAP, YKL-40, sCD14, and NfL were associated with faster cognitive decline and elevated dementia rate”

    Humansserum29 years

    Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. GFAP is linked with a higher risk of dementia in humans (HR 2.26 (ACD); HR 2.62 (AD); HR 2.93 (VaD)).

    “GFAP showed the strongest association with all dementia types (ACD: HR=2.26; AD: HR=2.62; VD: HR=2.93).”

    Humansin individuals with chronic pain; all-cause dementia, Alzheimer's disease and vascular dementian = 20,932

    Plasma proteomics reveals novel protein signatures associated with dementia in chronic pain individuals: a prospective cohort study

    AAIC 2025 abstract

  4. GFAP predicts dementia in MCI patients, on top of age, sex, and MMSE (C-index 0.69 [95%CI = 0.63; 0.76]).

    “For MCI patients who progressed to any form of dementia, plasma GFAP contributed on top of age, sex, and MMSE score in the parsimonious individualized prognostic model (C-index = 0.69 [95%CI = 0.63; 0.76]).”

    Humansin MCI patients, on top of age, sex, and MMSE

    Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly

    Alzheimer's research & therapy

  5. GFAP is linked with a higher risk of dementia in humans.

    “higher GFAP predicted faster cognitive decline, increased risk of CDR progression”

    Humans240 weeks

    Prognostic Value of Plasma Glial Fibrillary Acidic Protein in Cognitively Unimpaired Older Adults: Results from the A4 Study

    medRxiv : the preprint server for health sciencesPreprint

  6. GFAP is linked with a higher risk of dementia in humans following an MCI diagnosis (HR = 1.762 (95% CI: 1.367-2.271)).

    “Above other factors, higher baseline serum glial fibrillary acidic protein (HR = 1.762 (95% CI: 1.367-2.271)) and neurofilament light (HR = 1.467 (95% CI: 1.152-1.69)) associated with increased dementia risk.”

    Humansfollowing an MCI diagnosisserumn = 413

    Predictors of Bi-directional Transitions From Mild Cognitive Impairment in a Diverse Cohort

    The journals of gerontology. Series A, Biological sciences and medical sciences

  7. GFAP predicts dementia in humans (measured at least 10 years before diagnosis) (at least 10 years before diagnosis).

    “GFAP and NEFL began to change at least 10 years before dementia diagnosis.”

    Humansmeasured at least 10 years before diagnosisat least 10 years before diagnosisn = 52,645

    Plasma proteomic profiles predict future dementia in healthy adults

    Nature aging

  8. GFAP is associated with dementia.

    “a biomarker of reactive astrocytes and an emerging indicator of dementia”

    Review

    Role of astrocyte biomarker GFAP in early diagnosis and prognosis assessment of dementia: A comprehensive review

    International journal of biological macromolecules

More on Dementia

Age

upin humans4upin mice1

5 studies
  1. GFAP is associated with age in humans (non-dementia).

    “plasma GFAP levels were significantly correlated with age (p < 0.05).”

    Humansnon-dementian = 908

    Multidimensional modeling of biological aging: integrating gait, eye movement, rest-state functional connectivity, and plasma biomarkers in non-dementia older adults

    The journal of prevention of Alzheimer's disease

  2. Age is associated with GFAP in humans (adjusting for sex and education) (0.26).

    “Equally, significant positive associations were found for GFAP and age (0.26)”

    Humansadjusting for sex and education

    Alzheimer's Disease Biomarker-Nigeria (ADIBIO-N): Cohort description and baseline data report

    Journal of Alzheimer's disease : JAD

  3. Age is associated with GFAP in humans (Spearman's r=0.832, p<0.0001).

    “A strong positive correlation between age and plasma GFAP levels was observed (Spearman's r=0.832, p<0.0001).”

    Humans

    Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation

    Clinical chemistry and laboratory medicine

  4. Age is associated with GFAP in humans (control cohort) (r = 0.62, 95% CI 0.58-0.66, p<0.0001).

    “In the control cohort, a non-linear elevation of serum GFAP with increasing age was observed (Spearman correlation coefficient (r) 0.62, 95%CI 0.58-0.66, p<0.0001).”

    Humanscontrol cohortn = 952

    Age-specific control and Alzheimer’s disease reference curves and z-scores for glial fibrillary acidic protein in blood

    medRxivPreprint

  5. Age is associated with GFAP in mice (Ts1Cje mice and age-matched controls).

    “Quantification of neuronal and glial markers (n=11) revealed increases in GFAP, with an age effect, and S100B, with age and genotype effects.”

    AnimalsTs1Cje mice and age-matched controlscerebellum

    Specific age-related molecular alterations in the cerebellum of Down syndrome mouse models

    Brain research

Cognitive decline

upin humans5HR 1.61

5 studies
  1. GFAP predicts cognitive decline in humans (combined with high p-tau217) (HR 1.61 (1.41 – 1.84; p < 0.0001)).

    “Elevated GFAP was associated with the greatest hazards when combined with high p ‐tau217, HR 1.61 (1.41 – 1.84; p < 0.0001)”

    Humanscombined with high p-tau217plasman = 4,382

    Combining p ‐tau217 with Other Blood Biomarkers to Enhance Prediction of Cognitive Decline: A Large Memory Clinic Cohort Study

    AAIC 2025 abstract

  2. GFAP predicts cognitive decline in virologically suppressed people with HIV (MoCA change -2.9 vs. -1.3 (Q4 vs Q1-3)).

    “Elevated p-tau217 and GFAP predict cognitive decline in PWH”

    Humansin virologically suppressed people with HIVmedian 5.9 years

    Blood-based Alzheimer's disease biomarkers and cognitive trajectories in older people with HIV with undetectable viral loads

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. GFAP is associated with cognitive decline in humans.

    “higher baseline GFAP levels were significantly associated with higher rates of decline in PACC scores in women (ß=‐6.08, p = .001)”

    Humansserum240 weeksfemalesn = 695

    Sex and Age Differences in the Association of Serum GFAP Levels with Cognitive Decline in Cognitively Unimpaired Individuals: Results from the A4 Study

    AAIC 2025 abstract

  4. GFAP predicts cognitive decline in humans.

    “higher baseline plasma levels of GFAP, NFL, pTau181, and pTau217 independently predicted steeper cognitive decline”

    Humansplasmaup to 11 yearsn = 233

    Prediction of cognitive decline and Alzheimer's disease conversion by a plasma biomarker panel in non-demented individuals

    GeroScience

  5. GFAP is associated with cognitive decline in humans.

    “In isolated cognitive decliners, robust associations were observed for amyloid-β42, amyloid-β42/40 ratio and glial fibrillary acidic protein”

    Humansserum

    ASSOCIATION BETWEEN SERUM BIOMARKERS OF ALZHEIMER’S DISEASE AND “DUAL DECLINE” IN COGNITIVE AND MOTOR FUNCTIONS

    GSA 2024 abstract

All-cause dementia

upin humans4HR 2.25–2.47

4 studies
  1. GFAP is associated with all-cause dementia in humans (Worst quartile of GFAP) (HR 2.25; 95% CI 1.87-2.72).

    “GFAP (HR 2.25; 95% CI 1.87-2.72) had higher risk of dementia.”

    HumansWorst quartile of GFAP12.2-year median follow-up27.2% femalesn = 5,225

    Blood markers modestly predicted dementia in older adults

    Neurology

  2. GFAP is linked with a higher risk of all-cause dementia in chronic pain individuals; plasma proteomics (HR 2.26 for all-cause dementia (AD HR 2.62; VD HR 2.93)).

    “GFAP showed the strongest association with all dementia types (ACD: HR=2.26; AD: HR=2.62; VD: HR=2.93).”

    Humansin chronic pain individuals; plasma proteomics

    Plasma proteomics reveals novel protein signatures associated with dementia in chronic pain individuals: a prospective cohort study

    AAIC 2025 abstract

  3. GFAP is linked with a higher risk of all-cause dementia in humans (2.32 times more likely).

    “Individuals with higher GFAP levels were 2.32 times more likely to develop dementia.”

    Humansn = 52,645

    Plasma proteomic profiles predict future dementia in healthy adults

    Nature aging

  4. GFAP is associated with all-cause dementia in humans (Without prevalent dementia at baseline) (HR 2.47, 95% CI 1.52–4.01).

    “each standard deviation unit increase in log-transformed GFAP levels was significantly associated with a 2.5-fold higher risk of incident all-cause dementia”

    ReviewWithout prevalent dementia at baselinePer standard deviation increase in log-transformed GFAPUp to 15 yearsn = 4,338

    A population-based meta-analysis of circulating GFAP for cognition and dementia risk

    Annals of clinical and translational neurology

More on All-cause dementia

Mild cognitive impairment

upin humans4HR 2.19

4 studies
  1. GFAP is associated with mild cognitive impairment in humans (cognitively unimpaired individuals).

    “GFAP was associated with incident MCI/dementia due to both AD and non-AD.”

    Humanscognitively unimpaired individuals

    Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns

    medRxiv : the preprint server for health sciencesPreprint

  2. GFAP predicts mild cognitive impairment in individuals who developed amyloid-negative MCI (about 11 years before onset).

    “Individuals who developed amyloid-negative MCI showed abnormalities only in GFAP (about 11 years before onset) and YKL-40 (around the time of symptom onset).”

    Humansin individuals who developed amyloid-negative MCIplasma

    Plasma biomarker trajectories across Alzheimer's clinical onset: a 17-year prospective study

    Alzheimer's research & therapy

  3. GFAP predicts mild cognitive impairment in humans (HR = 2.19, adjusted HR = 1.70).

    “Elevated plasma GFAP predicted increased risk of conversion to MCI (HR = 2.19, p < 0.001; adjusted HR = 1.70, p = 0.0056)”

    Humansplasma

    Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease

    The journal of prevention of Alzheimer's disease

  4. GFAP is associated with mild cognitive impairment in humans (Multivariate analysis in a multi-ethnic Southeast Asian community cohort) (OR 3.64, 95% CI 1.96–6.75; p<0.001).

    “Multivariate analysis showed elevated plasma GFAP (OR=3.64, 95% CI:1.96–6.75, p<0.001) and higher MBI-C Mood scores (OR=2.61, 95% CI:1.54–4.44, p<0.001) as the variables most associated with MCI.”

    HumansMultivariate analysis in a multi-ethnic Southeast Asian community cohortplasma60.5% femalesn = 678

    The Combination of Neuropsychiatric Symptoms and Blood-Based Biomarkers Enhances Early Detection of Mild Cognitive Impairment

    medRxivPreprint

More on Mild cognitive impairment

Female sex

upin humans4

4 studies
  1. female sex is associated with GFAP in humans (cognitively unimpaired) (p = 0.001).

    “ANCOVA, controlling for age, showed significantly higher plasma GFAP levels in females compared to males ( p = 0.001).”

    Humanscognitively unimpairedplasman = 325

    Sex‐Differences in Association between Plasma GFAP and Cognition in Cognitively Unimpaired Community Dwelling Older Adults

    AAIC 2025 abstract

  2. Female sex is associated with GFAP in humans.

    “Biomarker differences, such as elevated GFAP in females and higher p ‐tau 181 in males, suggest underlying neurobiological mechanisms.”

    Humansfemalesn = 714

    Impact of Cerebrovascular Disease on Gender‐Specific Cognitive and Biomarker Profiles: Insights from the Southeast Asian BIOCIS Cohort

    AAIC 2025 abstract

  3. Female sex is associated with GFAP in humans.

    “sex-related differences were observed after age 50, with females showing higher absolute GFAP levels than males.”

    Humansfemales

    Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation

    Clinical chemistry and laboratory medicine

  4. Female sex is associated with GFAP in humans (177.5 pg/mL versus 157.73 pg/mL).

    “Female participants displayed higher GFAP (177.5 pg/mL vs 157.73 pg/mL; p = 0.002)”

    Humansplasmafemale versus males

    Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

    Neurology

APOE

upin humans3

3 studies
  1. APOE is associated with GFAP in humans (APOE ε4 carriers compared with non-carriers).

    “increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively.”

    HumansAPOE ε4 carriers compared with non-carriersplasma

    Alzheimer’s risk variant linked to steeper blood-marker changes

    Nature communications

  2. APOE is associated with GFAP in humans (p-value < 0.05).

    “Analysis showed that GFAP levels varied significantly ( p ‐value < 0.05) with age in addition to sex, APOE genotype, elevated amyloid PET, hippocampal atrophy, and cognitive status.”

    Humansplasma

    Cross‐Sectional Analysis of Plasma GFAP Across Alzheimer's Disease Stages

    AAIC 2025 abstract

  3. APOE is associated with GFAP in humans (apolipoprotein ε4 status) (β = 0.139 (95% CI 0.092-0.186), p < 0.001).

    “apolipoprotein ε4 status (β = 0.139 (95% CI 0.092-0.186), p < 0.001), and cognitive impairment (β = 0.150 (95% CI 0.103-0.197), p < 0.001) were positively associated with serum GFAP”

    Humansapolipoprotein ε4 statusserum65% females

    Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort

    Neurology

More on APOE

White matter hyperintensities

upin humans3

3 studies
  1. GFAP is associated with white matter hyperintensities in humans (posterior cerebral artery territory).

    “Higher plasma GFAP was associated with increased posterior cerebral artery (PCA)-defined WMH volume, but not with global amyloid or episodic memory.”

    Humansposterior cerebral artery territoryplasman = 439

    Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest-old, the LifeAfter90 Study

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. GFAP is associated with white matter hyperintensities in humans.

    “GFAP was positively associated with WMH.”

    Humanswhite mattern = 251

    Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer's disease in a diverse cohort: MESA

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. GFAP is associated with white matter hyperintensities in humans.

    “All measures (VRFs, gait, behavioral, plasma GFAP, plasma NfL) were associated with white matter hyperintensities (WMHs) but mainly in intermediate and high age strata.”

    Humans

    Vascular risk, gait, behavioral, and plasma indicators of VCID

    Alzheimer's & dementia : the journal of the Alzheimer's Association

More on White matter hyperintensities

TBI severity

upin humans1

1 study
  1. GFAP is associated with TBI severity in humans (acute phase post-TBI).

    “GFAP and NfL emerged as the most reliable biomarkers, strongly correlating with age, sex, TBI severity and temporal progression post‐injury.”

    Human trialacute phase post-TBIserum

    Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden

    AAIC 2025 abstract

All 163

Funding

3 grants since 2021

National Institute of Neurological Disorders and Stroke$332KAlzheimer's AssociationFonds Wetenschappelijk Onderzoek

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Blood GFAP is associated with older age and predicts cognitive decline and dementia in human cohorts. Human trials report lower GFAP after hearing interventions, lower plasma GFAP after neflamapimod in dementia with Lewy bodies, and higher cerebrospinal-fluid GFAP after dasatinib plus quercetin.

  2. Summary rewritten as its findings changed.

    As it read before

    Higher plasma GFAP associates with lower odds of reaching 90 without cognitive impairment in cognitively unimpaired women in a preprint. Human cohorts link GFAP to dementia risk and cognitive decline; studies report both prediction of amyloid positivity and no association with amyloid PET positivity. A hearing-intervention trial reports reduced GFAP in participants with untreated hearing loss.

  3. Summary rewritten as its findings changed.

    As it read before

    A human study links a Mediterranean diet to lower GFAP, whereas another reports no effect of rest–activity rhythms on GFAP.

  4. Summary written from the findings.

Latest

Dec 2025: 94Jan 2026: 47Feb 2026: 23Mar 2026: 30Apr 2026: 24May 2026: 18Jun 2026: 15Jul 2026: 19Aug 2026: 29Sep 2026: 24Oct 2026: 27Nov 2026: 13363 papers in 12 months
NPJ Parkinson's Disease

Some blood amino acids linked to lower Parkinson’s risk

A prospective cohort study of 374,751 UK Biobank participants linked higher levels of certain protein building blocks to a lower risk of developing Parkinson’s disease.A prospective cohort study of 374,751 UK Biobank participants linked higher levels of certain protein building blocks to a lower risk of developing Parkinson’s disease.

Cohort · 374,751 peopleParkinson's disease

See all 670 papers on GFAP